TMDX Q1 2026 Earnings Call Summary

1Key Financial Results and Metrics

Total Revenue: $174 million, up 21% year-over-year and 8% sequentially.

U.S. Transplant Product Revenue: $102 million, a 22% increase year-over-year and 7% sequentially.

International Revenue: $6 million, a 39% increase year-over-year and 17% sequentially.

Adjusted Operating Profit: Approximately $18.1 million, representing 10.4% of total revenue.

Cash Position: Ended the quarter with $462 million in cash and cash equivalents.

Gross Margin: Approximately 58%, down 331 basis points year-over-year due to increased internal supply chain activities and investments.

Adjusted Operating Expenses: $83 million, up 42% year-over-year, driven by R&D and SG&A investments.

2Strategic Updates and Business Highlights

Growth Initiatives:

Advancing heart and lung franchises through enhanced clinical programs (ENHANCE and DENOVO).

Developing the OCS Kidney platform, targeting the largest segment of the global transplant market.

Launch of the Controlled Hypothermic Organ Preservation System (CHOPS) to expand product offerings.

International expansion efforts in Europe, replicating the U.S. transplant logistics model.

NOP Services: Maintained coverage of approximately 82% of NOP missions requiring air transport, with plans to optimize fleet utilization.

3Forward Guidance and Outlook

2026 Revenue Guidance: Reiterated guidance of $727 million to $757 million, representing 20% to 25% growth over 2025.

Operating Margin: Expected to remain pressured in the near term but targeted to normalize towards 60% in the long term as investments yield results.

4Bad News, Challenges, or Points of Concern

Impact of U.S. Transplant Modernization Act: Noted transient negative effects on organ procurement organization (OPO) performance and donor numbers, with expectations of volatility in donor numbers continuing into Q2.

Competitive Pressures: Delays in clinical program enrollments due to competitive dynamics and market confusion, particularly affecting the ENHANCE and DENOVO programs.

Gross Margin Decline: The gross margin decreased year-over-year, attributed to increased supply chain costs and investments, with expectations that these pressures will persist in the short term.

5Notable Q&A Insights

CHOPS Strategy: CHOPS is positioned as an additive solution targeting short-distance heart transplants, not a replacement for existing products. The device aims to improve organ preservation compared to traditional methods.

ENHANCE and DENOVO Programs: Despite delays, management remains optimistic about the potential for these programs to drive market penetration, particularly in heart transplants.

Market Dynamics: Management acknowledged ongoing challenges in the donor market but expressed confidence in a rebound, citing historical trends.

Operating Margin Expectations: Management indicated that operating margins are expected to improve in the latter half of the year as investments begin to materialize. Overall, TMDX reported a solid start to 2026, with strong revenue growth and strategic initiatives aimed at expanding its market presence, despite facing challenges related to regulatory changes and competitive pressures.